Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Sparano on the Utility of Liquid Biopsies in Breast Cancer

January 21st 2020

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.

Dr. Kasi on Utility of Personalized Medicine in Colorectal Cancer

January 21st 2020

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Incorporating Precision Medicine into Oncology

January 21st 2020

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

NICE Cites Uncertainty in Deciding Against Larotrectinib in NTRK Fusion+ Solid Tumors

January 18th 2020

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Utility of Trapelo to Increase Molecular Testing Rates

January 18th 2020

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Dr. Hudson on Repeat Molecular Testing in Relapsed/Refractory NSCLC

January 18th 2020

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Dr. Yorio on Searching for Biomarkers in Metastatic Lung Cancer

January 18th 2020

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Dr. Robson on the Application of Precision Medicine in Breast Cancer

January 17th 2020

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Dr. Chittoor on Guidelines for Liquid Biopsies in NSCLC

January 15th 2020

Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.

Dr. Nordquist on Matching Patients to Clinical Trials

January 15th 2020

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Dr. Rohs on the Use Liquid Biopsies in Lung Cancer

January 14th 2020

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020